(Q43740784)

26 November 2017

title

A phase II trial of 9-aminocaptothecin (9-AC) as a 120-h infusion in patients with non-small cell lung cancer (English)

1 reference

26 November 2017

main subject

phase II clinical trial

0 references

1

Vokes EE

1 reference

26 November 2017

8

Golomb HM

1 reference

26 November 2017

Gordon GS

2

1 reference

26 November 2017

Rudin CM

3

1 reference

26 November 2017

Mauer AM

4

1 reference

26 November 2017

Watson S

5

1 reference

26 November 2017

Krauss S

6

1 reference

26 November 2017

Arrieta R

7

1 reference

26 November 2017

Hoffman PC

9

1 reference

26 November 2017

publication date

1 January 2001

1 reference

Investigational New Drugs

26 November 2017

published in

1 reference

26 November 2017

volume

19

1 reference

26 November 2017

issue

4

1 reference

26 November 2017

page(s)

329-333

1 reference

Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.

26 November 2017

cites work

1 reference

12 December 2020

Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients

1 reference

12 December 2020

Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer

1 reference

12 December 2020

Phase I and pharmacokinetic trial of weekly CPT-11

1 reference

12 December 2020

Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hr continuous infusion weekly for three weeks in metastatic colorectal carcinoma

1 reference

12 December 2020

Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients

1 reference

12 December 2020

Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma

1 reference

12 December 2020

9-Aminocamptothecin by 72-hour continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma.

1 reference

12 December 2020

Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors

1 reference

12 December 2020

Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer

1 reference

12 December 2020

Phase II trial of aminocamptothecin (9-AC/DMA) in patients with advanced squamous cell head and neck cancer

1 reference

12 December 2020

A phase II study of 9-aminocamptothecin in patients with refractory breast cancer

1 reference

12 December 2020

Topoisomerase I inhibitors: review and update

1 reference

12 December 2020

Phase II study of topotecan in metastatic non-small-cell lung cancer

1 reference

12 December 2020

1 reference

12 December 2020

Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer

1 reference

12 December 2020

A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer

1 reference

12 December 2020

Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies

1 reference

12 December 2020

Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks

1 reference

12 December 2020

A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin.

1 reference

12 December 2020

A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer

1 reference

12 December 2020

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and

1 reference

12 December 2020

Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1010674113243

1 reference

Dimensions Publication ID

26 November 2017

1017265336

0 references

1 reference